In the face of shifting consumer health trends, Novo’s online direct-to-patient pharmacy NovoCare has adapted in turn with a ...
The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the ...
In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged ...
On a hot streak, GSK has won a third high-profile FDA approval in recent weeks, this time for the second lung cancer drug ...
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a ...
No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. | Roche’s giredestrant took the ...
Winning a ruling in their favor Monday, AstraZeneca and its rare disease unit Alexion have successfully sidestepped U.S.
BeOne Medicines has expanded its partnership with CLL Society, entering into a three-year, $3 million pact to support ...
Novartis is eking out the life of its aging immunology med, Cosentyx, with another label expansion. | Cosentyx's latest FDA ...
Another pharma is revving into the auto racing zone, this time with Viatris pulling up as the Cadillac Formula 1 team’s ...
The observations largely centered on a lack of procedures that could lead to microbial and particulate contamination.
The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results